Skip to content

Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

Chronic Graft Versus Host Disease

This trial collects clinical data and blood samples to predict the quality of response to specific treatments in patients with chronic graft-versus-host disease (cGVHD) who are about to start initial or second-line therapy. Collecting and analyzing clinical data and blood samples from patients with cGVHD before and after treatment initiation may help doctors identify changes that may predict treatment response.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Prior allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis
* No evidence of persistent or progressive malignancy at the time of enrollment
* Agrees to be evaluated at the transplant center before initial or second-line treatment is started (may be concurrent with the enrollment visit), and later between 2-6 weeks, 3 months and 6 months after treatment is started or if a new therapy is started before 6 months
* Signed, informed consent

Exclusion Criteria:

* Inability to comply with study procedures
* Uncontrolled psychiatric disorder
* Anticipated survival \< 6 months

Lieu de l'étude

Vancouver General Hospital/BC Cancer
Vancouver General Hospital/BC Cancer
Vancouver, British Columbia
Canada

Contactez l'équipe d'étude

Primary Contact

Jennifer White

[email protected]
604-875-4863
Étude parrainée par
Fred Hutchinson Cancer Center
Participants recherchés
Plus d'informations
ID de l'étude: NCT04431479